Dermapharm Holding SE

DMPHFOTCHealthcare● Active

$59.00

+$19.44(+49.14%)

Market Cap$2.9B

P/E Ratio—

52W High$59

52W Low$39.56

Avg Volume219.2

Open$59.00

Beta0.88

Free Cash Flow Financials Revenue

Dermapharm Holding SE (DMPHF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

DMPHF · free cash flow · updated Jun 9, 2026

Core FCF metrics

DMPHF · FCF · TTM · margin & CAGR

Free cash flow was $139.3M for FY2025 (fiscal year ending 2025-12-31), down 14.6% year-over-year The FCF margin was 12.0%. Five-year CAGR stands at +9.1%.

FY2025 Free Cash Flow$139.3M▼ -14.6% YoY

Trailing 12M (TTM)$218.6Mtrailing 4 quarters sum

FCF Margin12.0%$139.3M ÷ revenue

3-Year CAGR-17.6%FY2022 → FY2025

5-Year CAGR+9.1%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

DMPHF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$181.4M(42M)$139.3M▼ 14.6%12.0%

FY2024$201.4M(38M)$163.1M▼ 8.3%13.8%

FY2023$219.4M(42M)$177.9M▼ 28.7%15.5%

FY2022$288.5M(39M)$249.5M▲ +31.9%24.4%

FY2021$250.4M(61M)$189.2M▲ +109.5%20.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

DMPHF · P/FCF · FCF yield · FCF per share

Dermapharm Holding SE (DMPHF) trades at a FCF yield of 8.52% and a price-to-free-cash-flow ratio of 14.5x. FCF per share stands at $4.06, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

8.52%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$4.06

TTM FCF ÷ Shares Outstanding

Price / FCF

x14.5

Share Price ÷ FCF per Share

EV / FCF (TTM)

x15.8

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

DMPHF · cash flow statement · operating / investing / financing

For FY2025, Dermapharm Holding SE generated $181.4M in operating cash flow and spent 42M in capital expenditures, yielding $139.3M in free cash flow.

Operating Activities

+$181.4M

Cash from core business operations

2025-12-31

Investing Activities

−$110.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$13.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($181.4M) − |CapEx| (42M) = FCF ($139.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

DMPHF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Dermapharm Holding SEYOU

DMPHF

$139.3M-14.6%12.0%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Dermapharm Holding SE (DMPHF) reported free cash flow of $139.3M for FY2025 (fiscal year ending 2025-12-31), down 14.6% year-over-year. The FCF margin was 12.0%.

Based on available data, Dermapharm Holding SE has maintained positive free cash flow for at least 12 fiscal year(s). FCF peaked at $249.5M in FY2022. The 5-year CAGR stands at +9.1%.

Dermapharm Holding SE's FCF yield is 8.52% and price-to-FCF ratio is 14.5x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

DMPHF free cash flow · 8 questions

Dermapharm Holding SE free cash flow was $139.3M for FY2025, down 14.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $218.6M.

DMPHF free cash flowDMPHF FCFDMPHF FCF 2025DMPHF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Dermapharm Holding SE · Dermapharm Holding SE SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026